Effects of reprogrammed splenic CD8 T-cells in vitro and in mice with spontaneous metastatic Lewis lung carcinoma.

BACKGROUND

Metastatic disease is a major and difficult-to-treat complication of lung cancer. Considering insufficient effectiveness of existing therapies and taking into account the current problem of lung cancer chemoresistance, it is necessary to continue the development of new treatments.

METHODS

Previously, we have demonstrated the antitumor effects of reprogrammed CD8 T-cells (rCD8 T-cells) from the spleen in mice with orthotopic lung carcinoma. Reprogramming was conducted by inhibiting the MAPK/ERK signalling pathway through MEKi and the immune checkpoint PD-1/PD-L1. Concurrently, CD8 T-cells were trained in Lewis lung carcinoma (LLC) cells. We suggested that rCD8 T-cells isolated from the spleen might impede the development of metastatic disease.

RESULTS

The present study has indicated that the reprogramming procedure enhances the survival and cytotoxicity of splenic CD8 T-cells in LLC culture. In an LLC model of spontaneous metastasis, splenic rCD8 + T-cell therapy augmented the numbers of CD8 T-cells and CD4 T-cells in the lungs of mice. These changes can account for the partial reduction of tumors in the lungs and the mitigation of metastatic activity.

CONCLUSIONS

Our proposed reprogramming method enhances the antitumor activity of CD8 T-cells isolated from the spleen and could be valuable in formulating an approach to treating metastatic disease in patients with lung cancer.